drugset / Trial / NCT03487042

Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo

NCT03487042

Phase 4 Unknown 40 enrolled Assiut University
SequentialOpen-labelTreatment

Summary

Vitiligo is a chronic disorder of pigmentation characterized by the development of white macules on the skin due to loss of epidermal melanocytes. It affects approximately 0.5%-2% of general population world-wide, without predilection for sex or race.Vitiligo can be classified into segmental or non-segmental. Non-segmental or generalized vitiligo is the most common clinical presentation and often involves the face and acral regions. Multiple monotherapy modalities are established to treat vitiligo but the response is variable, unsatisfactory, and requiring a prolonged course. This problem is exaggerated by the multifactorial and polygenic nature of the pathomechanism of the disease. These facts pave the way to combination therapy that showed better and safe repigmentation response than monotherapy.

Timeline

Start
2018-05
Primary completion
2019-12
Completion
2019-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.03 % Topical

Indications